In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation.
Since most clinical radiotherapy is given as multiple small irradiation fractions, the present study was undertaken to test the in vivo radiosensitizing activity of a new hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Radiosensitizing activity was measured by a growth delay assay using a transplanted mammary tumor in C3H/He mice, and by an in vivo-in vitro assay using the SCC VII tumor. KU-2285 was injected intraperitoneally 30 min before irradiation in all experiments. The in vivo-in vitro assay using SCC VII tumors showed that 12.5 micrograms/g of KU-2285 sensitized the tumors to irradiation (5 Gy/fr x 5 fr/48 hr or 6 Gy/fr x 3 fr/48 hr). KU-2285 also sensitized the transplanted mammary tumors to fractionated irradiation. We concluded that KU-2285 was able to sensitize two different murine tumors when given in combination with radiation dose fractionation.
Sasai
K
K
Department of Radiology, Faculty of Medicine, Kyoto University, Japan.
Fushiki
M
M
Yukawa
Y
Y
Suyama
S
S
Iwai
H
H
Shibamoto
Y
Y
Nishimoto
S
S
Takahashi
M
M
Abe
M
M
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D002470:Cell Survival / Q000528:radiation effects; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000532:radiotherapy; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009593:Nitroimidazoles / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D011879:Radiotherapy Dosage
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C069296:KU 2285